All In Biotech

Drug Trial Radar · NCT05758896

Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI

Effect on Contrast Induced Acute Kidney Injury of APX-115 in Subjects Undergoing Percutaneous Coronary Intervention A Randomized, Double-blind, Parallel Group, Multicenter, Multi-national Trial

Last checked: Nov 20, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 218 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

218

Actual

Start

Dec 27, 2023

Primary completion

Jul 22, 2026

Study completion Jul 22, 2026

Sponsor

Lead sponsor
Aptabio Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Mar 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase 2 study is to assess the safety and efficacy of APX-115 active doses in Contrast Induced Acute Kidney Disease compared to placebo following multiple oral dosing in patients with undergoing percutaneous coronary intervention. It is anticipated that approximately 230 patients will be randomized into the study in a 1:1 ratio to 400 mg APX-115 (Isuzinaxib hydrochloride) or placebo arm.

Conditions

  • Contrast Induced Acute Kidney Injury

Interventions

  • Isuzinaxib (APX-115)Drug

    Treatment allocation in 1:1 ratio to Isuzinaxib or Placebo

  • PlaceboDrug

    Treatment allocation in 1:1 ratio to Isuzinaxib or Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety endpoints: adverse eventTime frame: Day -2 to day 84
  2. Safety endpoints: vital signTime frame: Day 0 to day 84
  3. Safety endpoints: physical examTime frame: Day 0 to day 84
  4. Safety endpoints: ECGTime frame: Day 0 to day 84
  5. Safety endpoints: labsTime frame: Day 0 to day 84

Locations

14 sites in 2 countries. Site status is shown where the registry gives one.

  • Baylor Scott & White Research Institute

    Dallas, Texas

  • Kangwon National University Hospital

    Chuncheon, South Korea

  • Keimyung University Dongsan Hospital

    Daegu, South Korea

  • Chungnam National University Hospital

    Daejeon, South Korea

  • Inje University Ilsan Paik Hospital

    Goyang, South Korea

  • Chonnam National University Hospital

    Gwangju, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, South Korea

  • Kangbuk Samsung Hospital

    Seoul, South Korea

  • Korea University Anam Hospital

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • The Catholic University of Korea Seoul St. Mary's Hospital

    Seoul, South Korea

  • The Catholic University of Korea St. Vincent's Hospital

    Suwon, South Korea

  • Ulsan University Hospital

    Ulsan, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.